Search Result

Results for "

her2+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (3) CDK (2) DNA/RNA Synthesis (1) EGFR (41) ERK (1) Isotope-Labeled Compounds (1) PARP (2) Potassium Channel (1) Reference Standards (4)
By Research Areas:	Cancer (41) Inflammation/Immunology (1) Neurological Disease (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-16069

Tucatinib Maximum Cited Publications 15 Publications Verification Irbinitinib; ARRY-380; ONT-380	EGFR	Cancer
Tucatinib (Irbinitinib) is a potent, orally active and selective *HER2* inhibitor with an IC₅₀ of 8 nM.

HY-135815

Mobocertinib 10+ Cited Publications TAK-788; AP32788	EGFR	Cancer
Mobocertinib (TAK-788) is an orally active and irreversible *EGFR/HER2* inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research ^[2].

HY-13501

Mubritinib 5+ Cited Publications TAK-165	EGFR	Cancer
Mubritinib (TAK-165) is a potent and selective *EGFR2/HER2* inhibitor with an IC₅₀ of 6 nM.

HY-164718

Sevabertinib BAY 2927088	EGFR	Cancer
Sevabertinib (BAY 2927088) is an orally active and reversible dual *EGFR-HER2** inhibitor* (IC ⁵⁰ <0.5 nM for wild-type HER2, HER2 A775insYVMA, wild-type EGFR, and EGFR D770_N771insSVD). Sevabertinib has anticancer activity against lung cancer ^[2].

HY-10251

BMS-599626 3 Publications Verification AC480	EGFR	Cancer
BMS-599626 (AC480) is a selective and orally bioavailable HER1 and *HER2* inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy ^[2].

HY-172429

Enozertinib ORIC-114	EGFR	Neurological Disease Cancer
Enozertinib (ORIC-114) is an orally active, CNS-penetrant, highly selective and irreversible dual *EGFR/HER2** inhibitor* that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib can be used for the research of solid tumors and NSCLC ^[2].

HY-16069A

Tucatinib hemiethanolate Maximum Cited Publications 15 Publications Verification Irbinitinib hemiethanolate; ARRY-380 hemiethanolate; ONT-380 hemiethanolate	EGFR	Cancer
Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective *HER2* inhibitor with an IC₅₀ of 8 nM.

HY-150024

BI-4142	EGFR	Cancer
BI-4142 is a potent, highly selective and orally active *HER2* inhibitor with an IC₅₀ of 5 nM .

HY-17632

Tarloxotinib bromide 1 Publications Verification TH-4000	EGFR	Cancer
Tarloxotinib bromide (TH-4000) is an irreversible *EGFR/HER2* inhibitor.

HY-135815A

Mobocertinib succinate 10+ Cited Publications TAK-788 succinate; AP32788 succinate	EGFR	Cancer
Mobocertinib (TAK-788) succinate is an orally active and irreversible *EGFR/HER2* inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research ^[2].

HY-12010

BMS-599626 Hydrochloride 3 Publications Verification AC480 Hydrochloride	EGFR	Cancer
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and *HER2* inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy ^[2].

HY-172429A

Enozertinib hemihydrate ORIC-114 hemihydrate	EGFR	Neurological Disease Cancer
Enozertinib (ORIC-114) hemihydrate is an orally active, CNS-penetrant, highly selective and irreversible dual *EGFR/HER2** inhibitor* that exhibits potent and targeted inhibition of exon 20 insertion mutations. Enozertinib hemihydrate exhibits high kinome selectivity for the EGFR family of receptors to reduce off-target kinase liabilities. Enozertinib hemihydrate induces tumor regression and demonstrates antitumor activity in central nervous system and non-small cell lung cancer (NSCLC) tumor models. Enozertinib hemihydrate can be used for the research of solid tumors and NSCLC ^[2] .

HY-155079

DZD1516	EGFR	Cancer
DZD1516 is a potent and selective *HER2* inhibitor (IC₅₀=0.56 nM) with good blood-brain permeability. DZD1516 exhibits antitumor activity in CNS and subcutaneous xenograft mouse models .

HY-143319

SPH5030	EGFR	Cancer
SPH5030 is a selective and irreversible *HER2* inhibitor. SPH5030 inhibits HER2 ^WT and EGFR ^WT with IC₅₀s of 3.51 and 8.13 nM, respectively. SPH5030 shows excellent activities against HER2 mutants. SPH5030 can be used for the research of cancer .

HY-111553

TAS0728	EGFR	Cancer
TAS0728 is a potent, selective, orally active, irreversible and covalent-binding *HER2* inhibitor, with an IC₅₀ of 13 nM. TAS0728 also shows IC₅₀s of 4.9, 8.5, 31, 65, 33, 25 and 86 nM for BMX、HER4、BLK、EGFR、JAK3、SLK and LOK respectively. Furthermore, TAS0728 exhibits robust and sustained inhibition of the phosphorylation of *HER2, HER3*, and downstream effectors .

HY-108931

AG 1406	EGFR	Cancer
AG 1406 (compound M19) is a *HER2* inhibitor, with an IC₅₀ of 10.57 μM for HER2 in BT474 cell and >50 μM for EGFR in EGF-3T3 cell .

HY-172970

HQY1428	CDK DNA/RNA Synthesis Apoptosis	Cancer
HQY1428 is an orally active CDK12 inhibitor. HQY1428 inhibits DNA replication, causes G2/M arrest in SKOV3 cells, induces DNA double-strand breaks and apoptosis. HQY1428 has anti-tumor activity in the SKOV3 xenograft mouse model. HQY1428 combined with the HER2 inhibitor Lapatinib (HY-50898) in the NCI-N87 xenograft mouse model produces a synergistic therapeutic effect .

HY-143733

HER2-IN-5	EGFR	Cancer
HER2-IN-5 is a potent and orally active *HER-2* inhibitor, example 10, extracted from patent WO2021164697 .

HY-16069R

Tucatinib (Standard) Irbinitinib (Standard); ARRY-380 (Standard); ONT-380 (Standard)	EGFR Reference Standards	Cancer
Tucatinib (Standard) is the analytical standard of Tucatinib. This product is intended for research and analytical applications. Tucatinib (Irbinitinib) is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.

HY-151162

HER2-IN-12	EGFR	Cancer
HER2-IN-12 is a *HER2* inhibitor (IC₅₀: 121 nM). HER2-IN-12 can be used in the research of cancers, such as breast cancer .

HY-16069S

Tucatinib-d6 Irbinitinib-d₆; ARRY-380-d₆; ONT-380-d₆	Isotope-Labeled Compounds EGFR	Cancer
Tucatinib-d₆ (Irbinitinib-d₆) is deuterium labeled Tucatinib. Tucatinib (Irbinitinib) is a potent, orally active and selective *HER2* inhibitor with an IC₅₀ of 8 nM .

HY-176744

HER2-IN-22	EGFR Apoptosis	Cancer
HER2-IN-22 is a potent and selective *HER2* inhibitor with an IC₅₀ of 215 μM. HER2-IN-22 possesses killing activity against various tumor cells and can induce cell apoptosis. HER2-IN-22 significantly inhibits tumor growth. HER2-IN-22 can be used in the study for tumors such as HER2+ breast cancer .

HY-178116

HER2-IN-23	EGFR PARP	Cancer
HER2-IN-23 is a selective *HER2* inhibitor. HER2-IN-23 reduces in total HER2 expression rather than in phosphorylated HER2 (p-HER2). HER2-IN-23 reduces cyclin D1 level and stimulates PARP cleavage. HER2-IN-23 can be used for the study of HER2-positive breast cancer .

HY-156639

*EGFR/ErbB-2 inhibitor-1*	EGFR	Cancer
EGFR/ErbB-2 inhibitor-1 is a ErbB2/HER2 inhibitor .

HY-155079A

(R)-DZD1516	EGFR	Others
(R)-DZD1516 is the R enantiomer of DZD1516 (HY-155079). DZD1516 is a potent and selective HER2 inhibitor .

HY-16069AR

Tucatinib hemiethanolate (Standard) Irbinitinib hemiethanolate (Standard); ARRY-380 hemiethanolate (Standard); ONT-380 hemiethanolate (Standard)	EGFR Reference Standards	Cancer
Tucatinib (hemiethanolate) (Standard) is the analytical standard of Tucatinib (hemiethanolate). This product is intended for research and analytical applications. Tucatinib (Irbinitinib) hemiethanolate is a potent, orally active and selective HER2 inhibitor with an IC50 of 8 nM.

HY-163419

HER2-IN-18	EGFR	Cancer
HER2-IN-18 is a *HER2* inhibitor, with an IC₅₀ less than 200 nM for HER-YVMA and HER-WT. HER2-IN-18 can be used for cancer research .

HY-153557

HER2-IN-13	EGFR Potassium Channel	Cancer
HER2-IN-13 (Compound 33) is an *HER2* inhibitor with an IC₅₀ of 8 nM. HER2-IN-13 also inhibits wt-EGFR with an IC₅₀ of 0.40 μM .

HY-153557A

HER2-IN-14	EGFR	Cancer
HER2-IN-14 (Compound 34) is an *HER2* inhibitor with an IC₅₀ of 18 nM. HER2-IN-14 also inhibits wt-EGFR with an IC₅₀ of 6.3 μM .

HY-144097

HER2-IN-8	EGFR	Inflammation/Immunology Cancer
HER2-IN-8 is a *HER-2* inhibitor extracted from patent WO2021179274A1 compound 107. HER2-IN-8 can be used for the research of cancer and inflammation .

HY-W008914

(E/Z)-CP-724714	EGFR	Cancer
(E/Z)-CP-724714 is a racemic compound of (E)-CP-724714 and (Z)-CP-724714 isomers. CP-724714 is a potent and selective orally active ErbB2 (HER2) inhibitor .

HY-153111

EGFR/HER2-IN-9	EGFR	Cancer
EGFR/HER2-IN-9 (Compound 1) is an EGFR and *HER2* inhibitor with IC₅₀s of 3.2, 8.3 and 14 nM against EGFR, EGFR T790M and HER2, respectively .

HY-135815B

Mobocertinib mesylate TAK-788 mesylate; AP32788 mesylate	EGFR	Cancer
Mobocertinib (TAK-788) mesylate is an orally active and irreversible *EGFR/HER2* inhibitor. Mobocertinib mesylate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib mesylate can be used in NSCLC research ^[2].

HY-162623

EGFR/HER2-IN-15	EGFR	Cancer
EGFR/HER2-IN-15, a dihydropyrimidine, is a potent *EGFR/HER2* inhibitor. EGFR/HER2-IN-15 significantly inhibits EGFR ^wt activity with an IC₅₀ of 37.21 nM. EGFR/HER2-IN-15 has anticaner effects .

HY-157399

EGFR/HER2-IN-10	EGFR	Cancer
EGFR/HER2-IN-10 (compound 9F) is a potent and selective dual *EGFR/HER2* inhibitor with IC₅₀s of 2.3 nM and 234 nM for EGFR and HER2, respectively. EGFR/HER2-IN-10 shows an effective antiproliferative action against prostate carcinoma .

HY-143323

HER2-IN-9	EGFR	Cancer
HER2-IN-9 is an orally active *HER2* inhibitor, with an IC₅₀ value of 0.03 μM. HER2-IN-9 inhibits HER-2 positive breast cancer cells proliferation and migration. HER2-IN-9 can be used in the research of breast cancers .

HY-135815R

Mobocertinib (Standard) TAK-788 (Standard); AP32788 (Standard)	EGFR Reference Standards	Cancer
Mobocertinib (Standard) is the analytical standard of Mobocertinib. This product is intended for research and analytical applications. Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research ^[2].

HY-164489

KU004	EGFR Akt ERK Apoptosis	Cancer
KU004 is a potent dual *EGFR/HER2* inhibitor with anticancer effects. KU004 inhibits the proliferation of human breast cancer SKBR3 cells by inducing G1 phase arrest. KU004 blocks the activation of *HER2, EGFR* and downstream Akt and Erk pathways and induces cell Apoptosis mainly via the extrinsic pathway. KU004 is a quinazoline derivative ^[2].

HY-172160

HER2-IN-21	EGFR	Cancer
HER2-IN-21 (compound 657994) is a human epidermal growth factor receptor 2 (HER2) inhibitor, with an IC₅₀ of 3.85 μM .

HY-177895

IAM1363	EGFR	Cancer
IAM1363 is a selective, irreversible and brain-penetrant *HER2* inhibitor. IAM1363 shows over 1,000-fold selectivity for HER2 compared to EGFR. IAM1363 can be used for the study of advanced HER2 cancers, such as HER2-driven non-small cell lung cancer (NSCLC) .

HY-135815AR

Mobocertinib succinate (Standard) TAK-788 succinate (Standard); AP32788 succinate (Standard)	EGFR Reference Standards	Cancer
Mobocertinib (succinate) (Standard) is the analytical standard of Mobocertinib (succinate). This product is intended for research and analytical applications. Mobocertinib (TAK-788) succinate is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib succinate potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib succinate can be used in NSCLC research ^[2].

HY-178119

HER4/HER2-IN-1	EGFR CDK PARP	Cancer
HER4/HER2-IN-1 (Compound 4b) is a *HER4/HER2* inhibitor. HER4/HER2-IN-1 inhibits the proliferation of HER2-positive cells. HER4/HER2-IN-1 reduces the total expression level of HER2 in A431 cells, while the phosphorylated HER2 (p-HER2) does not decrease. HER4/HER2-IN-1 lowers the level of cell cycle protein D1 (cyclin D1) and stimulates the cleavage of PARP. HER4/HER2-IN-1 can be used for the study of cancer, such as breast cancer .

Tucatinib-d6
Tucatinib-d₆ (Irbinitinib-d₆) is deuterium labeled Tucatinib. Tucatinib (Irbinitinib) is a potent, orally active and selective *HER2* inhibitor with an IC₅₀ of 8 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: